,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,880,2,1,,29215023,5852,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
1,880,2,1,,29215023,5852,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
2,881,2,2,,29215023,5852,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
3,894,2,1,,29215023,5852,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
4,1030,2,1,,29215023,5852,Inconclusive,30582681.0,216.0,22.3872,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
5,1379,1,2,,29215023,5852,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
6,1452,1,1,,29215023,5852,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
7,1457,1,1,,29215023,5852,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
8,1460,1,3,,29215023,5852,Inconclusive,92096784.0,4137.0,25.1189,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
9,1463,1,1,,29215023,5852,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
10,1467,1,3,,29215023,5852,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
11,1468,1,1,,29215023,5852,Inconclusive,92096784.0,4137.0,7.9433,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
12,1469,1,1,,29215023,5852,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
13,1471,2,1,,29215023,5852,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
14,1476,2,1,,29215023,5852,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
15,1477,1,1,,29215023,5852,Inconclusive,,,5.0119,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
16,1478,2,1,,29215023,5852,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
17,1479,1,2,,29215023,5852,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
18,1487,1,1,,29215023,5852,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
19,1490,2,1,,29215023,5852,Active,10954339.0,,25.1189,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
20,1688,1,1,,29215023,5852,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
21,1766,1,1,,29215023,5852,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
22,1766,1,1,,29215023,5852,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
23,1768,1,1,,29215023,5852,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
24,1768,1,1,,29215023,5852,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
25,1865,1,1,,29215023,5852,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
26,1948,1,1,,29215023,5852,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
27,2101,1,1,,29215023,5852,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
28,2107,1,1,,29215023,5852,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
29,2112,1,1,,29215023,5852,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
30,2314,1,2,,29215023,5852,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
31,2314,1,2,,29215023,5852,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
32,2315,1,2,,29215023,5852,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
33,2315,1,2,,29215023,5852,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
34,2451,1,2,,29215023,5852,Active,122920737.0,,12.5594,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
35,2472,1,2,,29215023,5852,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
36,2517,2,1,,144204450,5852,Inactive,6980812.0,,0.0056,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
37,2528,1,2,,29215023,5852,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
38,2546,1,1,,29215023,5852,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
39,2549,1,1,,29215023,5852,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
40,2551,1,1,,29215023,5852,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
41,2662,2,1,,29215023,5852,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
42,26336,3,3,,103508277,5852,Unspecified,,,,,pKa value was determined,Other,11212129.0,
43,152781,6,2,,103508277,5852,Unspecified,,,30.0,IC50,Inhibitory concentration against TNF-alpha production from human peripheral blood mononuclear cells stimulated by LPS,Confirmatory,11229767.0,
44,152782,6,2,,103508277,5852,Unspecified,,,30.0,IC50,Inhibitory concentration against growth of LPS stimulated human peripheral blood mononuclear cells,Confirmatory,11229767.0,
45,171540,2,4,,103508277,5852,Unspecified,,,,,Cartilage space narrowing was measured radiographically after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
46,172966,3,3,,103508277,5852,Unspecified,,,,,"Compound was tested for antiinflammatory activity by immune response to collagen II antigen in rats, antibody titer was determined by passive hemagglutinination",Other,3086558.0,
47,175768,3,3,,103508277,5852,Unspecified,,,,,Delayed Type hypersensitivity (DTH) is measured by increase in ear thickness 24 hours after antigen injection into pinna,Other,3086558.0,
48,180216,2,4,,103508277,5852,Unspecified,,,,,Erosions of tarsal bones measured radiographically after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
49,182193,3,3,,103508277,5852,Unspecified,,,,,"Antiinflammatory activity against collagen II arthritis in rats, activity % inhibition in noninjected paw edema",Other,3086558.0,
50,182194,3,3,,103508277,5852,Unspecified,,,,,"Antiinflammatory activity against collagen II arthritis in rats, activity% inhibition in injected paw edema",Other,3086558.0,
51,186888,2,4,,103508277,5852,Unspecified,,,,,Paw diameter measured with a micrometer caliper after 42 days initial immunization with type II collagen in rats at a dose of 200 mg/kg,Other,,
52,187883,3,3,,103508277,5852,Unspecified,,,,,"Compound was tested for antiinflammatory activity against collagen II arthritis in rats,",Other,3086558.0,
53,187884,4,3,,103508277,5852,Unspecified,,,,,"compound was tested for antiinflammatory activity against collagen II arthritis in rats,",Other,3086558.0,
54,209812,8,4,,103508277,5852,Inconclusive,,,,,Inhibitory concentration against T cell proliferation determined by MTS assay using concanavalin A (Con A)-stimulated mice spleen cells; NT = Not tested,Other,11229767.0,
55,265520,3,3,,103508277,5852,Unspecified,,,,,"Distribution of copper per 100 ml of Wistar rat blood at 5 mg/kg, iv after 1 hr",Other,16581247.0,
56,265521,10,1,,103508277,5852,Inconclusive,,,,,"Distribution of copper in Wistar rat CSF at 5 mg/kg, iv after 1 hr",Other,16581247.0,
57,265522,6,1,,103508277,5852,Unspecified,,,,,"Distribution of copper in Wistar rat brain cortex at 5 mg/kg, iv after 1 hr",Other,16581247.0,
58,265523,6,1,,103508277,5852,Unspecified,,,,,"Distribution of copper in Wistar rat brain corpus callosum at 5 mg/kg, iv after 1 hr",Other,16581247.0,
59,289327,6,2,,103508277,5852,Active,,,4.9,IC50,Singlet oxygen scavenging activity by assessed as inhibition of DHR oxidation,Confirmatory,17624791.0,
60,302622,3,9,,103508277,5852,Unspecified,115878.0,286762.0,,,Inhibition of bovine ZnCPD pretreated for 200 seconds at 1.5 mM assessed as transfer of zinc(II) from ZnCPD to chelator 4-(2-pyridylazo)-resorcinol,Other,17918925.0,
61,302623,3,9,,103508277,5852,Unspecified,115878.0,286762.0,,,Inhibition of bovine ZnCPD pretreated at 0.25 mM assessed as residual enzyme activity in presence of 1 mM ethylenediaminetetraacetic acid within 20 mins,Other,17918925.0,
62,302624,3,9,,103508277,5852,Unspecified,115878.0,286762.0,,,Inhibition of bovine ZnCPD pretreated at 5 mM assessed as residual enzyme activity in presence of 1 mM ethylenediaminetetraacetic acid within 7 mins,Other,17918925.0,
63,302625,3,9,,103508277,5852,Unspecified,115878.0,286762.0,,,Inhibition of bovine ZnCPD pretreated at 0.25 mM assessed as residual enzyme activity in presence of 2.5 uM thionenin after 17 mins,Other,17918925.0,
64,314066,7,1,,103508277,5852,Active,,,,,Peroxynitrite scavenging activity assessed as inhibition of DHR 123 oxidation,Other,18178435.0,
65,377831,6,2,,103508277,5852,Active,,,3.3,IC50,Antioxidant activity assessed as authentic peroxynitrite free radical scavenging activity after 30 mins,Confirmatory,15844957.0,
66,377832,6,2,,103508277,5852,Active,,,4.4,IC50,Antioxidant activity assessed as 3-morpholinosydnonimine-derived peroxynitrite free radical scavenging activity after 30 mins,Confirmatory,15844957.0,
67,409945,3,9,,103508277,5852,Inactive,113978.0,4128.0,,,Inhibition of human recombinant MAOA at 100 uM by fluorimetric method,Other,18834112.0,
68,409949,3,9,,103508277,5852,Inactive,113978.0,4128.0,,,Inhibition of human liver MAOA,Other,18834112.0,
69,409951,3,9,,103508277,5852,Inactive,113980.0,4129.0,,,Inhibition of human liver MAOB,Other,18834112.0,
70,409954,4,9,,103508277,5852,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
71,467024,11,2,,103508277,5852,Unspecified,1169224.0,950999.0,50.0,IC50,Inhibition of Haemophilus influenzae recombinant DapE,Confirmatory,19822427.0,
72,485281,1,1,,29215023,5852,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
73,485290,1,1,,29215023,5852,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
74,492961,1,1,,29215023,5852,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
75,504327,1,1,,29215023,5852,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
76,504332,1,1,,29215023,5852,Inconclusive,168985070.0,,5.0119,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
77,504749,1,3,,29215023,5852,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
78,504749,1,3,1.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
79,504749,1,3,2.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
80,504749,1,3,3.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
81,504749,1,3,4.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
82,504749,1,3,5.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
83,504749,1,3,6.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
84,504749,1,3,7.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
85,504749,1,3,8.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
86,504749,1,3,9.0,29215023,5852,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
87,504749,1,3,10.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
88,504749,1,3,11.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
89,504749,1,3,12.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
90,504749,1,3,13.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
91,504749,1,3,14.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
92,504749,1,3,15.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
93,504749,1,3,16.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
94,504749,1,3,17.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
95,504749,1,3,18.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
96,504749,1,3,19.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
97,504749,1,3,20.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
98,504749,1,3,21.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
99,504749,1,3,22.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
100,504749,1,3,23.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
101,504749,1,3,24.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
102,504749,1,3,25.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
103,504749,1,3,26.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
104,504749,1,3,27.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
105,504749,1,3,28.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
106,504749,1,3,29.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
107,504749,1,3,30.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
108,504749,1,3,31.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
109,504749,1,3,32.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
110,504749,1,3,33.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
111,504749,1,3,34.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
112,504749,1,3,35.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
113,504749,1,3,36.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
114,504749,1,3,37.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
115,504749,1,3,38.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
116,504749,1,3,39.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
117,504749,1,3,40.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
118,504749,1,3,41.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
119,504749,1,3,42.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
120,504749,1,3,43.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
121,504749,1,3,44.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
122,504749,1,3,45.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
123,504749,1,3,46.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
124,504749,1,3,47.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
125,504749,1,3,48.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
126,504749,1,3,49.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
127,504749,1,3,50.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
128,504749,1,3,51.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
129,504749,1,3,52.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
130,504749,1,3,53.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
131,504749,1,3,54.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
132,504749,1,3,55.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
133,504749,1,3,56.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
134,504749,1,3,57.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
135,504749,1,3,58.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
136,504749,1,3,59.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
137,504749,1,3,60.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
138,504749,1,3,61.0,29215023,5852,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
139,504832,1,1,,29215023,5852,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
140,504834,1,1,,29215023,5852,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
141,504847,1,1,,29215023,5852,Inconclusive,63054845.0,7421.0,44.6684,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
142,504865,1,1,,29215023,5852,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
143,540276,1,2,,29215023,5852,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
144,540276,1,2,,50104281,5852,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
145,588211,2,3,,103508277,5852,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
146,588212,2,3,,103508277,5852,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
147,588213,2,3,,103508277,5852,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
148,588214,2,3,,103508277,5852,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
149,588215,2,3,,103508277,5852,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
150,588216,2,3,,103508277,5852,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
151,588217,2,3,,103508277,5852,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
152,588218,2,3,,103508277,5852,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
153,588219,2,3,,103508277,5852,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
154,588579,1,1,,29215023,5852,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
155,588834,2,1,,144204450,5852,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
156,602332,1,1,,29215023,5852,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
157,624030,1,2,,29215023,5852,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
158,624031,1,2,,29215023,5852,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
159,624032,1,2,,29215023,5852,Inactive,8393992.0,24660.0,0.0128,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
160,624044,1,2,,29215023,5852,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
161,624170,1,1,,29215023,5852,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
162,624172,1,1,,29215023,5852,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
163,624173,1,3,,29215023,5852,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
164,624296,1,1,,29215023,5852,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
165,624297,1,1,,29215023,5852,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
166,625144,5,5,,103508277,5852,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
167,625145,4,7,,103508277,5852,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
168,625146,5,5,,103508277,5852,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
169,625147,4,7,,103508277,5852,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
170,625148,4,7,,103508277,5852,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
171,625149,4,7,,103508277,5852,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
172,625150,5,5,,103508277,5852,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
173,625151,4,7,,103508277,5852,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
174,625152,4,7,,103508277,5852,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
175,625153,4,7,,103508277,5852,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
176,625154,4,7,,103508277,5852,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
177,625155,4,7,,103508277,5852,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
178,625156,1,9,,103508277,5852,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
179,625157,6,2,,103508277,5852,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
180,625158,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
181,625159,5,5,,103508277,5852,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
182,625160,1,9,,103508277,5852,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
183,625161,4,7,,103508277,5852,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
184,625162,4,7,,103508277,5852,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
185,625163,4,7,,103508277,5852,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
186,625164,1,6,,103508277,5852,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
187,625165,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
188,625166,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
189,625167,5,5,,103508277,5852,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
190,625168,4,7,,103508277,5852,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
191,625169,1,6,,103508277,5852,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
192,625170,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
193,625171,4,7,,103508277,5852,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
194,625172,4,7,,103508277,5852,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
195,625173,5,5,,103508277,5852,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
196,625174,5,5,,103508277,5852,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
197,625175,5,5,,103508277,5852,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
198,625176,1,9,,103508277,5852,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
199,625177,5,5,,103508277,5852,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
200,625178,5,5,,103508277,5852,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
201,625179,1,9,,103508277,5852,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
202,625180,5,5,,103508277,5852,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
203,625181,5,5,,103508277,5852,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
204,625182,5,5,,103508277,5852,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
205,625183,5,5,,103508277,5852,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
206,625184,5,5,,103508277,5852,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
207,625185,5,5,,103508277,5852,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
208,625186,5,5,,103508277,5852,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
209,625187,5,5,,103508277,5852,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
210,625188,1,9,,103508277,5852,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
211,625189,1,7,,103508277,5852,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
212,625190,4,5,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
213,625191,4,7,,103508277,5852,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
214,625192,4,7,,103508277,5852,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
215,625193,5,5,,103508277,5852,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
216,625194,4,7,,103508277,5852,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
217,625195,4,7,,103508277,5852,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
218,625196,5,6,,103508277,5852,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
219,625197,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
220,625198,4,7,,103508277,5852,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
221,625199,4,7,,103508277,5852,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
222,625200,4,7,,103508277,5852,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
223,625201,4,7,,103508277,5852,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
224,625202,4,7,,103508277,5852,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
225,625203,4,7,,103508277,5852,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
226,625204,4,7,,103508277,5852,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
227,625205,4,7,,103508277,5852,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
228,625206,4,7,,103508277,5852,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
229,625207,4,7,,103508277,5852,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
230,625208,5,5,,103508277,5852,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
231,625209,4,7,,103508277,5852,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
232,625210,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
233,625211,1,6,,103508277,5852,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
234,625212,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
235,625213,4,7,,103508277,5852,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
236,625214,1,9,,103508277,5852,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
237,625215,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
238,625216,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
239,625217,4,7,,103508277,5852,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
240,625218,4,7,,103508277,5852,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
241,625219,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
242,625220,4,7,,103508277,5852,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
243,625221,4,7,,103508277,5852,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
244,625222,4,7,,103508277,5852,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
245,625223,4,7,,103508277,5852,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
246,625224,3,4,,103508277,5852,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
247,625225,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
248,625226,4,7,,103508277,5852,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
249,625227,4,7,,103508277,5852,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
250,625228,4,7,,103508277,5852,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
251,625229,5,5,,103508277,5852,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
252,625230,1,6,,103508277,5852,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
253,625231,4,7,,103508277,5852,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
254,625232,1,9,,103508277,5852,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
255,625233,4,7,,103508277,5852,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
256,625234,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
257,625235,4,7,,103508277,5852,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
258,625236,5,5,,103508277,5852,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
259,625237,4,7,,103508277,5852,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
260,625238,4,7,,103508277,5852,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
261,625239,4,7,,103508277,5852,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
262,625240,1,9,,103508277,5852,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
263,625241,4,7,,103508277,5852,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
264,625242,4,7,,103508277,5852,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
265,625243,5,5,,103508277,5852,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
266,625244,5,5,,103508277,5852,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
267,625245,5,5,,103508277,5852,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
268,625246,1,9,,103508277,5852,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
269,625247,5,5,,103508277,5852,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
270,625248,5,5,,103508277,5852,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
271,625249,5,5,,103508277,5852,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
272,625250,5,5,,103508277,5852,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
273,625251,5,5,,103508277,5852,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
274,625252,4,7,,103508277,5852,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
275,625253,4,7,,103508277,5852,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
276,625254,4,7,,103508277,5852,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
277,625255,4,7,,103508277,5852,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
278,625256,4,7,,103508277,5852,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
279,625257,4,7,,103508277,5852,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
280,625258,4,7,,103508277,5852,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
281,625259,4,7,,103508277,5852,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
282,625260,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
283,625261,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
284,625262,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
285,625263,4,7,,103508277,5852,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
286,625264,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
287,625265,1,6,,103508277,5852,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
288,625266,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
289,625267,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
290,625268,4,2,,103508277,5852,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
291,625268,4,2,,103508277,5852,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
292,625268,4,2,,103508277,5852,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
293,625268,4,2,,103508277,5852,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
294,625269,4,7,,103508277,5852,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
295,625270,4,7,,103508277,5852,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
296,625271,5,5,,103508277,5852,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
297,625272,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
298,625273,4,6,,103508277,5852,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
299,625274,1,6,,103508277,5852,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
300,625275,3,4,,103508277,5852,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
301,625277,1,3,,103508277,5852,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
302,625279,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
303,625280,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
304,625281,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
305,625282,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
306,625283,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
307,625284,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
308,625285,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
309,625286,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
310,625287,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
311,625288,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
312,625289,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
313,625290,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
314,625291,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
315,625292,1,3,,103508277,5852,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
316,651631,4,1,,144204450,5852,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
317,651632,4,1,,144204450,5852,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
318,651633,4,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
319,651634,4,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
320,652048,1,2,,144204450,5852,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
321,652051,1,1,,144204450,5852,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
322,666942,2,2,,103508277,5852,Active,,,1.0,IC50,Antioxidant activity assessed as authentic peroxynitrite radical scavenging activity after 5 mins by spectrophotometry,Confirmatory,22652051.0,
323,666943,2,2,,103508277,5852,Active,,,1.0,IC50,Antioxidant activity assessed as morpholinosydnonimine-derived peroxynitrite free radical scavenging activity after 5 mins by spectrophotometry,Confirmatory,22652051.0,
324,686978,1,1,,144204450,5852,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
325,686979,1,1,,144204450,5852,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
326,695851,1,2,,103508277,5852,Unspecified,,,,,"Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp",Other,21657271.0,
327,695876,2,3,,103508277,5852,Unspecified,,,6930.0,IC50,Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay,Confirmatory,21657271.0,
328,695877,2,3,,103508277,5852,Unspecified,,,4040.0,IC50,Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay,Confirmatory,21657271.0,
329,720516,2,1,,144204450,5852,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
330,720532,1,1,,144204450,5852,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
331,720533,1,1,,144204450,5852,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
332,720552,2,1,,144204450,5852,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
333,720634,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
334,720635,2,1,,144204450,5852,Inconclusive,,,10.5909,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
335,720637,2,1,,144204450,5852,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
336,720674,2,2,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
337,720675,2,2,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
338,720678,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
339,720679,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
340,720680,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
341,720681,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
342,720682,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
343,720683,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
344,720684,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
345,720685,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
346,720686,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
347,720687,2,2,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
348,720691,4,1,,144204450,5852,Inactive,311348376.0,2908.0,13.4481,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
349,720692,3,1,,144204450,5852,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
350,720693,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
351,720719,2,1,,144204450,5852,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
352,720725,2,1,,144204450,5852,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
353,743012,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
354,743014,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
355,743015,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
356,743033,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
357,743035,2,1,,144204450,5852,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
358,743036,2,1,,144204450,5852,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
359,743040,3,1,,144204450,5852,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
360,743041,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
361,743042,3,1,,144204450,5852,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
362,743053,2,1,,144204450,5852,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
363,743054,2,1,,144204450,5852,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
364,743063,2,1,,144204450,5852,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
365,743064,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
366,743065,3,1,,144204450,5852,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
367,743066,3,1,,144204450,5852,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
368,743067,2,1,,144204450,5852,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
369,743069,2,1,,144204450,5852,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
370,743074,2,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
371,743075,2,1,,144204450,5852,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
372,743077,2,1,,144204450,5852,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
373,743078,2,1,,144204450,5852,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
374,743079,3,1,,144204450,5852,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
375,743080,3,1,,144204450,5852,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
376,743081,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
377,743083,3,1,,144204450,5852,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
378,743084,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
379,743085,3,1,,144204450,5852,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
380,743086,3,1,,144204450,5852,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
381,743091,2,1,,144204450,5852,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
382,743094,3,1,,144204450,5852,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
383,743122,2,1,,144204450,5852,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
384,743139,2,1,,144204450,5852,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
385,743140,2,1,,144204450,5852,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
386,743244,1,1,,144204450,5852,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
387,743344,1,1,,174006777,5852,Inactive,,,21.1177,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
388,743345,1,1,,174006777,5852,Inactive,,,0.0027,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
389,743346,1,1,,174006777,5852,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
390,743347,1,1,,174006777,5852,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
391,781325,1,2,,103508277,5852,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009,Other,24249037.0,
392,858741,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 441/7,Other,,
393,858742,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 441/7,Other,,
394,858743,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 441/7,Other,,
395,858744,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 441/7,Other,,
396,858745,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 441/7,Other,,
397,858746,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 441/7,Other,,
398,858747,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 441/7,Other,,
399,858748,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 441/7,Other,,
400,858749,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 441/7,Other,,
401,858750,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 441/7,Other,,
402,858751,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 441/7,Other,,
403,858752,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 441/7,Other,,
404,858753,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 441/7,Other,,
405,858754,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 441/7,Other,,
406,858755,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 441/7,Other,,
407,858756,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 441/8,Other,,
408,858757,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 441/8,Other,,
409,858758,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 441/8,Other,,
410,858759,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 441/8,Other,,
411,858760,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 441/8,Other,,
412,858761,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 441/8,Other,,
413,858795,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 441/15,Other,,
414,858796,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 441/15,Other,,
415,858797,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 441/15,Other,,
416,858798,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 441/15,Other,,
417,858799,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 441/15,Other,,
418,858800,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 441/15,Other,,
419,858801,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 441/15,Other,,
420,858802,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 441/15,Other,,
421,858803,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 441/15,Other,,
422,858804,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 441/15,Other,,
423,858805,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 441/15,Other,,
424,858806,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 441/15,Other,,
425,858807,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 441/15,Other,,
426,858808,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 441/15,Other,,
427,858809,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 441/15,Other,,
428,858810,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 441/15,Other,,
429,858811,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 441/15,Other,,
430,858812,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 441/15,Other,,
431,858813,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 441/15,Other,,
432,858814,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 441/15,Other,,
433,858815,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 441/15,Other,,
434,858816,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 441/16,Other,,
435,858817,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 441/16,Other,,
436,858818,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 441/16,Other,,
437,858819,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 441/16,Other,,
438,858820,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 441/16,Other,,
439,858821,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 441/16,Other,,
440,858822,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 441/16,Other,,
441,858823,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 441/16,Other,,
442,858824,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 441/16,Other,,
443,858825,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 441/16,Other,,
444,858826,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 441/16,Other,,
445,858827,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 441/16,Other,,
446,858828,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 441/16,Other,,
447,858829,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 441/16,Other,,
448,858830,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 441/16,Other,,
449,858831,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 441/16,Other,,
450,859503,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 441/16,Other,,
451,859504,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 441/16,Other,,
452,859505,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 441/16,Other,,
453,859506,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 441/16,Other,,
454,859507,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 441/16,Other,,
455,860172,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 440/11,Other,,
456,860173,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 440/11,Other,,
457,860174,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 440/11,Other,,
458,860175,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 440/11,Other,,
459,860176,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 440/11,Other,,
460,860177,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 440/11,Other,,
461,860178,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 440/11,Other,,
462,860179,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 440/11,Other,,
463,931000,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011211,Other,,
464,931001,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011211,Other,,
465,931002,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011211,Other,,
466,931003,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011211,Other,,
467,931004,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011211,Other,,
468,931005,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011211,Other,,
469,931006,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011211,Other,,
470,933649,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011211,Other,,
471,933650,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011211,Other,,
472,933651,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011211",Other,,
473,933652,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011211,Other,,
474,933653,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011211,Other,,
475,933654,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011211,Other,,
476,933655,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011211,Other,,
477,933656,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011211,Other,,
478,933657,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011211,Other,,
479,933658,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011211,Other,,
480,933659,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011211,Other,,
481,933660,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011211,Other,,
482,940275,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011211,Other,,
483,940276,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011211,Other,,
484,940277,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011211,Other,,
485,940278,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011211,Other,,
486,940279,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011211,Other,,
487,940280,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011211,Other,,
488,940281,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011211,Other,,
489,940282,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011211,Other,,
490,940283,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011211,Other,,
491,940284,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011211,Other,,
492,940285,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011211,Other,,
493,940286,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011211,Other,,
494,940287,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011211,Other,,
495,940288,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011211",Other,,
496,940289,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011211,Other,,
497,940290,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011211,Other,,
498,940291,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011211,Other,,
499,940292,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011211,Other,,
500,940293,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011211,Other,,
501,940553,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011211,Other,,
502,940554,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011211,Other,,
503,940555,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011211,Other,,
504,940556,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011211,Other,,
505,940557,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011211,Other,,
506,940558,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011211,Other,,
507,940559,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011211,Other,,
508,940560,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011211",Other,,
509,940561,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011211,Other,,
510,940562,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011211,Other,,
511,940563,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011211,Other,,
512,940564,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011211,Other,,
513,940565,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011211,Other,,
514,940566,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011211,Other,,
515,941195,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011211,Other,,
516,941196,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011211,Other,,
517,941197,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011211,Other,,
518,941198,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011211,Other,,
519,941199,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011211,Other,,
520,948333,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011211,Other,,
521,948334,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011211,Other,,
522,948335,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011211,Other,,
523,948336,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011211",Other,,
524,948337,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011211,Other,,
525,948338,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011211,Other,,
526,948339,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011211,Other,,
527,948340,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011211,Other,,
528,948341,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011211,Other,,
529,948342,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011211,Other,,
530,948343,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011211,Other,,
531,948344,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011211,Other,,
532,948345,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011211,Other,,
533,948346,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011211,Other,,
534,948347,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011211,Other,,
535,948348,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011211,Other,,
536,948349,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011211,Other,,
537,948475,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011211,Other,,
538,948476,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011211,Other,,
539,956001,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011211,Other,,
540,956002,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011211,Other,,
541,956003,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011211,Other,,
542,956004,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011211,Other,,
543,956005,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011211,Other,,
544,956006,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011211,Other,,
545,956007,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011211,Other,,
546,956008,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011211,Other,,
547,956009,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011211,Other,,
548,956010,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011211,Other,,
549,956011,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011211,Other,,
550,956012,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011211,Other,,
551,956013,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011211,Other,,
552,956014,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011211,Other,,
553,956015,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011211,Other,,
554,956582,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011211,Other,,
555,956583,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011211,Other,,
556,956584,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011211,Other,,
557,956585,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011211,Other,,
558,964331,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011211,Other,,
559,964332,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011211,Other,,
560,964333,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011211,Other,,
561,964334,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011211,Other,,
562,964335,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011211,Other,,
563,964336,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011211,Other,,
564,964337,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011211,Other,,
565,964338,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011211,Other,,
566,964339,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011211,Other,,
567,964340,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011211,Other,,
568,964341,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011211,Other,,
569,964342,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011211,Other,,
570,964343,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011211,Other,,
571,964344,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011211,Other,,
572,964345,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011211,Other,,
573,964346,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011211,Other,,
574,964347,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011211,Other,,
575,964348,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011211,Other,,
576,964349,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011211,Other,,
577,966495,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011211,Other,,
578,966718,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011211,Other,,
579,966719,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011211,Other,,
580,966720,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011211,Other,,
581,966721,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011211,Other,,
582,966722,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011211,Other,,
583,966723,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011211,Other,,
584,966724,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011211,Other,,
585,966725,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011211,Other,,
586,966726,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011211,Other,,
587,966727,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011211,Other,,
588,966728,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011211,Other,,
589,966729,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011211,Other,,
590,966730,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011211,Other,,
591,966731,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011211,Other,,
592,966732,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011211,Other,,
593,966733,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011211,Other,,
594,966734,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011211,Other,,
595,966735,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011211,Other,,
596,975508,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011211,Other,,
597,975509,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011211,Other,,
598,975510,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011211,Other,,
599,975511,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011211,Other,,
600,975512,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011211,Other,,
601,975513,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011211,Other,,
602,975514,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011211,Other,,
603,975515,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011211,Other,,
604,975516,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011211,Other,,
605,975517,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011211,Other,,
606,975518,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011211,Other,,
607,975519,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011211,Other,,
608,975520,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011211,Other,,
609,975521,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011211,Other,,
610,975522,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011211,Other,,
611,975523,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011211,Other,,
612,975524,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011211,Other,,
613,975525,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011211,Other,,
614,975526,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011211,Other,,
615,977599,1,1,,103508277,5852,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
616,977602,1,2,,103508277,5852,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
617,985879,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011211",Other,,
618,985880,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
619,985881,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011211,Other,,
620,985882,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011211",Other,,
621,985883,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
622,985884,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011211",Other,,
623,985885,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
624,985886,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
625,985887,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011211",Other,,
626,985888,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011211",Other,,
627,985889,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011211,Other,,
628,985890,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
629,985891,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011211",Other,,
630,985892,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011211",Other,,
631,985893,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
632,985894,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011211",Other,,
633,985895,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011211",Other,,
634,985896,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011211",Other,,
635,985897,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011211",Other,,
636,985898,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011211,Other,,
637,985899,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011211",Other,,
638,985900,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011211",Other,,
639,985901,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011211",Other,,
640,985902,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011211,Other,,
641,986485,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011211",Other,,
642,986486,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011211",Other,,
643,986487,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
644,986488,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011211",Other,,
645,986489,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011211",Other,,
646,986490,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011211",Other,,
647,993292,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011211",Other,,
648,993293,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011211",Other,,
649,993294,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011211",Other,,
650,993295,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011211",Other,,
651,993296,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011211",Other,,
652,993297,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011211,Other,,
653,993298,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011211",Other,,
654,993299,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011211,Other,,
655,993300,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011211",Other,,
656,993301,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011211",Other,,
657,993302,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011211",Other,,
658,993303,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011211",Other,,
659,993304,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011211",Other,,
660,993305,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011211",Other,,
661,993306,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011211",Other,,
662,993307,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011211",Other,,
663,993890,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
664,993891,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011211",Other,,
665,993892,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
666,993893,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011211",Other,,
667,993894,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011211",Other,,
668,993895,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
669,993896,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
670,993897,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011211",Other,,
671,993898,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011211",Other,,
672,993899,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
673,993900,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011211",Other,,
674,1025877,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011211",Other,,
675,1025878,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011211",Other,,
676,1025879,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011211",Other,,
677,1025880,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011211",Other,,
678,1025881,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011211",Other,,
679,1025882,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011211,Other,,
680,1025883,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011211",Other,,
681,1025884,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011211,Other,,
682,1025885,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011211",Other,,
683,1025886,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011211",Other,,
684,1025887,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011211",Other,,
685,1025888,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011211",Other,,
686,1025889,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011211",Other,,
687,1025890,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011211",Other,,
688,1025891,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011211",Other,,
689,1025892,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011211",Other,,
690,1025893,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
691,1025894,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011211",Other,,
692,1025895,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
693,1025896,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011211",Other,,
694,1025897,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011211",Other,,
695,1025898,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
696,1025899,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
697,1025900,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011211",Other,,
698,1025901,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011211",Other,,
699,1025902,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
700,1025903,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011211",Other,,
701,1025904,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011211",Other,,
702,1025905,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
703,1025906,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S011211,Other,,
704,1025907,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011211,Other,,
705,1025908,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011211,Other,,
706,1028361,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011211",Other,,
707,1028362,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
708,1028363,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011211",Other,,
709,1028364,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011211,Other,,
710,1028365,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
711,1028366,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
712,1028367,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011211",Other,,
713,1028368,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011211",Other,,
714,1028369,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011211,Other,,
715,1028370,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011211",Other,,
716,1028371,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011211",Other,,
717,1028372,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011211",Other,,
718,1028373,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011211",Other,,
719,1028374,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011211",Other,,
720,1028375,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011211",Other,,
721,1028376,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011211",Other,,
722,1028377,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S011211,Other,,
723,1028378,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011211",Other,,
724,1028379,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011211,Other,,
725,1028380,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011211",Other,,
726,1028381,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011211",Other,,
727,1028382,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011211",Other,,
728,1028383,1,3,,103508277,5852,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011211,Other,,
729,1028384,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011211",Other,,
730,1028385,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011211",Other,,
731,1028386,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011211",Other,,
732,1028387,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011211",Other,,
733,1028388,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011211",Other,,
734,1028389,1,3,,103508277,5852,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011211",Other,,
735,1035505,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/14,Other,,
736,1035506,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/14,Other,,
737,1035507,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/14,Other,,
738,1035508,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/14,Other,,
739,1035509,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/14,Other,,
740,1035510,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/15,Other,,
741,1035511,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/15,Other,,
742,1035512,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/15,Other,,
743,1035513,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/15,Other,,
744,1035514,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/15,Other,,
745,1035515,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/16,Other,,
746,1035516,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/16,Other,,
747,1035517,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/16,Other,,
748,1035518,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/16,Other,,
749,1035519,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/16,Other,,
750,1036077,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/5,Other,,
751,1036078,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/5,Other,,
752,1036079,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/5,Other,,
753,1036080,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/5,Other,,
754,1036081,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/5,Other,,
755,1036082,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/6,Other,,
756,1036083,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/6,Other,,
757,1036084,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/6,Other,,
758,1036085,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/6,Other,,
759,1036086,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/6,Other,,
760,1036087,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/7,Other,,
761,1036088,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/7,Other,,
762,1041141,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/7,Other,,
763,1041142,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/7,Other,,
764,1041143,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/7,Other,,
765,1041144,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/8,Other,,
766,1041145,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/8,Other,,
767,1041146,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/8,Other,,
768,1041147,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/8,Other,,
769,1041148,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/8,Other,,
770,1041149,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/9,Other,,
771,1041150,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/9,Other,,
772,1041151,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/9,Other,,
773,1041152,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/9,Other,,
774,1041153,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/9,Other,,
775,1041154,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/10,Other,,
776,1041155,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/10,Other,,
777,1041156,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/10,Other,,
778,1041157,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/10,Other,,
779,1041158,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/10,Other,,
780,1041159,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/11,Other,,
781,1041160,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/11,Other,,
782,1041161,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/11,Other,,
783,1041162,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/11,Other,,
784,1041163,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/11,Other,,
785,1041164,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/12,Other,,
786,1041165,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/12,Other,,
787,1041166,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/12,Other,,
788,1041167,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/12,Other,,
789,1041168,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/12,Other,,
790,1041169,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/13,Other,,
791,1041170,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/13,Other,,
792,1041171,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/13,Other,,
793,1041843,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/13,Other,,
794,1041844,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/13,Other,,
795,1041845,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/14,Other,,
796,1041846,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/14,Other,,
797,1041847,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/14,Other,,
798,1041848,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/14,Other,,
799,1041849,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/14,Other,,
800,1041850,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/15,Other,,
801,1041851,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/15,Other,,
802,1041852,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/15,Other,,
803,1041853,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/15,Other,,
804,1041854,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/15,Other,,
805,1041855,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 440/16,Other,,
806,1041856,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 440/16,Other,,
807,1041857,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 440/16,Other,,
808,1041858,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 440/16,Other,,
809,1044002,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 440/16,Other,,
810,1044003,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/5,Other,,
811,1044004,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/5,Other,,
812,1044005,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/5,Other,,
813,1044006,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/5,Other,,
814,1044007,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/5,Other,,
815,1044008,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/6,Other,,
816,1044009,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/6,Other,,
817,1044010,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/6,Other,,
818,1044011,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/6,Other,,
819,1044012,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/6,Other,,
820,1044013,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/7,Other,,
821,1044014,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/7,Other,,
822,1044015,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/7,Other,,
823,1044016,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/7,Other,,
824,1044017,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/7,Other,,
825,1044018,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/8,Other,,
826,1044019,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/8,Other,,
827,1044020,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/8,Other,,
828,1044021,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/8,Other,,
829,1044022,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/8,Other,,
830,1044023,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/9,Other,,
831,1044024,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/9,Other,,
832,1044690,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/9,Other,,
833,1044691,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/9,Other,,
834,1044692,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/9,Other,,
835,1044693,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/10,Other,,
836,1044694,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/10,Other,,
837,1044695,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/10,Other,,
838,1044696,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/10,Other,,
839,1044697,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/10,Other,,
840,1044698,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/11,Other,,
841,1044699,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/11,Other,,
842,1044700,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/11,Other,,
843,1044701,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/11,Other,,
844,1044702,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/11,Other,,
845,1044703,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/12,Other,,
846,1044704,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/12,Other,,
847,1044705,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/12,Other,,
848,1044706,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/12,Other,,
849,1044707,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/12,Other,,
850,1044708,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 441/13,Other,,
851,1044709,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 441/13,Other,,
852,1044710,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 441/13,Other,,
853,1044711,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 441/13,Other,,
854,1044712,1,2,,103508277,5852,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 441/13,Other,,
855,1075914,1,2,,103508277,5852,Active,,,,,Antioxidant activity assessed as peroxynitrite scavenging activity at 1 to 10 uM by DHR 123 assay,Other,24508132.0,
856,1077164,1,1,,103508277,5852,Unspecified,,,,,Antibacterial activity against Escherichia coli after 12 hrs by MTT assay,Other,24594526.0,
857,1077165,1,1,,103508277,5852,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa after 12 hrs by MTT assay,Other,24594526.0,
858,1077166,1,1,,103508277,5852,Unspecified,,,,,Antibacterial activity against Bacillus subtilis after 12 hrs by MTT assay,Other,24594526.0,
859,1077167,1,1,,103508277,5852,Unspecified,,,,,Antibacterial activity against Bacillus thuringiensis after 12 hrs by MTT assay,Other,24594526.0,
860,1079931,1,1,,103508277,5852,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
861,1079932,1,1,,103508277,5852,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
862,1079933,1,1,,103508277,5852,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
863,1079934,1,1,,103508277,5852,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
864,1079935,1,1,,103508277,5852,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
865,1079936,1,1,,103508277,5852,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
866,1079937,1,1,,103508277,5852,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
867,1079938,1,1,,103508277,5852,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
868,1079939,1,1,,103508277,5852,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
869,1079940,1,1,,103508277,5852,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
870,1079941,1,1,,103508277,5852,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
871,1079942,1,1,,103508277,5852,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
872,1079943,1,1,,103508277,5852,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
873,1079944,1,1,,103508277,5852,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
874,1079945,1,1,,103508277,5852,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
875,1079946,1,1,,103508277,5852,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
876,1079947,1,1,,103508277,5852,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
877,1079948,1,1,,103508277,5852,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
878,1079949,1,1,,103508277,5852,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
879,1117301,1,2,,144204450,5852,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
880,1117302,1,2,,144204450,5852,Inactive,,,2.2387,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
881,1117303,1,2,,144204450,5852,Inactive,,,3.55,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
882,1117311,1,1,,144204450,5852,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
883,1117315,1,1,,144204450,5852,Inactive,,,2.2387200000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
884,1117318,1,1,,144204450,5852,Inactive,,,3.5481300000000005,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
885,1119916,1,3,,103508277,5852,Unspecified,75409699.0,,,,Inhibition of Sphingomonas paucimobilis recombinant SPT expressed in Escherichia coli BL21(DE3) assessed as remaining activity at 5 mM after 30 mins by dialysis technique relative to control,Other,,
886,1119917,1,3,,103508277,5852,Unspecified,75409699.0,,,,Reversible inhibition of Sphingomonas paucimobilis recombinant SPT expressed in Escherichia coli BL21(DE3) assessed as restoration of enzyme activity at 5 mM after 30 mins by dialysis technique in presence of PLP relative to control,Other,,
887,1147022,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, po administered with 65 mmol/kg ethanol-1-[14C] measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
888,1147023,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, po administered 1 hr prior to 65 mmol/kg ethanol-1-[14C] treatment measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
889,1147024,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, ip administered 1 hr prior to 65 mmol/kg ethanol-1-[14C] treatment measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
890,1147025,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, po administered 1 hr prior to 65 mmol/kg ethanol-1-[14C] treatment measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
891,1147026,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 2 mmol/kg, ip administered first dose at 0.25 hrs prior to 43.5 mmol/kg ethanol-1-[14C] treatment followed by 4 doses of compound at 0.75 hrs, 3 hrs, 5 hrs, 7 hrs measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
892,1147027,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor pargyline/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, ip administered 1 hr prior to 65 mmol/kg ethanol-1-[14C] treatment measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
893,1147028,1,2,,103508277,5852,Unspecified,,,,,"Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor pyrogallol/ethanol-1-[14C]-treated Sprague-Dawley rat assessed as [14C]-3-acetyl-2,5,5-trimethylthiazolidine-4-carboxylic acid excretion in urine by measuring administered dose of ethanol-1-[14C] at 8.1 mmol/kg, ip administered 1 hr prior to 65 mmol/kg ethanol-1-[14C] treatment measured for 24 hrs by inverse isotope dilution method in presence of Ac2O relative to control",Other,364061.0,
894,1147029,1,1,,103508277,5852,Active,,,,,"Detoxification of acetaldehyde in aldehyde dehydrogenase inhibitor disuifiram/ethanol-treated rat assessed as reduction of blood acetaldehyde level at 8 mmol/kg, po administered 24 hrs prior to ethanol treatment measured after 1 hr by head space gas chromatographic analysis",Other,364061.0,
895,1159550,3,1,,252402550,5852,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
896,1159580,2,1,,268734657,5852,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
897,1209455,1,2,,103508277,5852,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
898,1209456,1,2,,103508277,5852,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
899,1209457,1,1,,103508277,5852,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
900,1224824,1,1,,174006777,5852,Inactive,,,2.9566,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
901,1224825,1,1,,174006777,5852,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
902,1224857,2,1,,174006777,5852,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
903,1224859,2,1,,174006777,5852,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
904,1259252,1,1,,174006777,5852,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
905,1259253,1,1,,174006777,5852,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
906,1259255,1,1,,174006777,5852,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
907,1259256,1,1,,174006777,5852,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
908,1259310,1,1,,332876133,5852,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
909,1259310,1,1,,332876753,5852,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
910,1259344,1,1,,144204450,5852,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
911,1259355,1,1,,144204450,5852,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
912,1259356,1,1,,144204450,5852,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
913,1259407,1,1,,363900854,5852,Active,,,,,CCRIS mutagenicity studies,Other,,
914,1259416,1,2,,340080784,5852,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
915,1259421,1,1,,340080784,5852,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
